Nacif v. Athira Pharma Inc

District Court, W.D. Washington·Decided November 1, 2024·No. 2:21-cv-00861·Unknown

Opinion

1 2

3 UNITED STATES DISTRICT COURT 4 WESTERN DISTRICT OF WASHINGTON AT SEATTLE 5 ANTONIO BACHAALANI NACIF; 6 WIES RAFI; and HANG GAO, 7 individually and on behalf of all others similarly situated, 8 Plaintiffs, C21-0861 TSZ 9 v. ORDER AND JUDGMENT 10 ATHIRA PHARMA, INC.; and LEEN KAWAS, Ph.D., 11 Defendants. 12

13 THIS MATTER comes before the Court on (i) plaintiffs’ motion, docket no. 134, 14 for final approval of a proposed class settlement; (ii) a motion for attorneys’ fees, 15 litigation costs, and service awards, docket no. 131, brought by Class Counsel (the firms 16 of Glancy Prongay & Murray LLP and Labaton Keller Sucharow LLP), liaison counsel 17 (the firm of Rossi Vucinovich, P.C.), and counsel for plaintiff Hang Gao (the firm of 18 Block & Leviton LLP); and (iii) a motion for attorneys’ fees and litigation costs, docket 19 no. 133, brought by counsel for movants Timothy Slyne and Tai Slyne (the firms of 20 Keller Rohrback L.L.P. and Longman Law, P.C.). Having conducted a hearing on 21 October 25, 2024 (the “Final Approval Hearing”) and having reviewed all papers filed in 22 connection with the motions, the Court enters the following Order and Judgment. 1 Background 2 This class action was commenced in June 2021 by Fan Wang and plaintiff Hang

3 Gao, who were represented by the firms of Tousley Brain Stephens PLLC and Block & 4 Leviton LLP (the “Block Firm”). See Compl. (docket no. 1). In August 2021, Timothy 5 Slyne and Tai Slyne (collectively, the “Slynes”) sought appointment as lead plaintiffs to 6 represent a portion of the class proposed in the original complaint. See Slynes’ Mot. 7 (docket no. 32). By Order entered October 5, 2021, the Slynes’ motion was denied, and 8 the following individuals were appointed as co-lead plaintiffs: (i) Antonio Bachaalani

9 Nacif; and (ii) Wies Rafi. Order at 6–9 (docket no. 60). Nacif’s and Rafi’s attorneys, the 10 firms of Labaton Sucharow LLP (the “Labaton Firm”) and Glancy Prongay & Murray 11 LLP (the “Glancy Firm”), respectively, were appointed as lead counsel, and the firm of 12 Rossi Vucinovich, P.C. (the “Rossi Firm”) was appointed as one of two liaison counsel; 13 the other liaison counsel has since withdrawn. See id. at 9; see also Notice of Withdrawal

14 (docket no. 67). 15 On January 7, 2022, plaintiffs Nacif and Rafi filed their Consolidated Amended 16 Complaint (“CAC”), docket no. 74, in which they asserted the following claims: 17 1. Violation of § 10(b) of the Securities Exchange Act of 1934 (“Exchange Act”), 15 U.S.C. § 78j(b), and of Rule 10b-5, 17 C.F.R. § 240.10b-5; 18 2. Violation of § 20(a) of the Exchange Act, 15 U.S.C. § 78t(a); 19 3. Violation of § 11 of the Securities Act of 1933 (“Securities Act”), 15 U.S.C. § 77k; 20 4. Violation of § 12(a)(2) of the Securities Act, 15 U.S.C. § 77l(a)(2); and 21 5. Violation of § 15 of the Securities Act, 15 U.S.C. § 77o. 22 1 The first, third, and fourth claims were asserted against all defendants, namely (a) Athira 2 Pharma, Inc. (“Athira”), (b) Leen Kawas, Ph.D., (c) Athira’s Chief Financial Officer

3 (“CFO”) Glenna Mileson, (d) Athira’s Board of Directors members Joseph Edelman, 4 John M. Fluke, Jr., and James A. Johnson (collectively “the Directors”), and (e) the 5 underwriters for Athira’s stock offerings, (i) Jefferies LLC, (ii) Goldman Sachs & Co. 6 LLC, (iii) Stifel, Nicolaus & Company, Incorporated, and (iv) JMP Securities LLC 7 (collectively, “the Underwriters”). The second and fifth claims were alleged against the 8 individual defendants (Kawas, CFO Mileson, and the Directors). The various claims

9 concerned eleven (11) statements made in the prospectuses for Athira’s initial public 10 offering (“IPO”) and second public offering (“SPO”) and in other materials filed with the 11 U.S. Securities and Exchange Commission (“SEC”). See Order at 24–27 (docket no. 89). 12 By Order entered July 29, 2022, the Court dismissed, upon defendants’ motion, all 13 claims in this matter except the third and fifth (Securities Act) claims, which remained

14 pending solely with respect to Statement 3 and against only Athira and Kawas. See id. at 15 29–49. Plaintiffs Nacif and Rafi were granted leave to file an amended complaint, but 16 they failed to do so by the deadline set by the Court. See Minute Order at ¶ 1 (docket 17 no. 91); see also Order at 2–3 & 5–6 (docket no. 114) (concluding that plaintiffs Nacif’s 18 and Rafi’s “decision not to timely amend their operative pleading renders ‘final’ the

19 earlier dismissal without prejudice”). In February 2023, Nacif, Rafi, Athira, and Kawas 20 participated in mediation before Jed D. Melnick of JAMS, Inc., and in March 2023, these 21 parties advised the Court that they had reached a settlement. See Stip. Mot. at 1, ¶¶ 4–5 22 (docket no. 117). In late April 2023, plaintiffs filed their first motion for preliminary 1 approval of a proposed settlement. This first motion was deferred pending receipt of 2 additional information, see Minute Order (docket no. 119), and ultimately denied by

3 Order entered September 27, 2023, see Order (docket no. 123). 4 In refusing to preliminarily approve the initially proposed settlement, the Court 5 concluded that, because plaintiffs Nacif and Rafi were bound by their decision not to 6 replead the previously dismissed Exchange Act claims, their positions were not typical of 7 those of the absent putative class members, and that, because the only way that plaintiff 8 Nacif, who has no Securities Act claims, could recover from this lawsuit was through

9 settlement, his interests were antagonistic toward all those he sought to represent. See id. 10 at 5–7. The Court further reasoned that, because the proposed settlement established no 11 limit on the portion of the settlement proceeds from which class members who have no 12 viable Securities Act claims could recover, the Court could not certify that the proposed 13 settlement treated putative class members equitably relative to each other. Id. at 7–9.

14 In December 2023, plaintiffs Nacif and Rafi, joined by plaintiff Gao, again sought 15 preliminary approval of a proposed settlement. See Pls.’ Renewed Mot. (docket no. 125). 16 To address the conflict of interest identified in the Court’s September 2023 Order, Gao’s 17 attorneys (Jacob Walker and Michael Gaines of the Block Firm) had participated in a 18 mediation session conducted by Jed Melnick on November 16, 2023, and they signed the

19 Amended Stipulation and Agreement of Settlement (“Settlement Agreement”), Ex. 1 to 20 Hoffman Decl. (docket no. 125-2), on Gao’s behalf. Order at 3 (docket no. 128) (citing 21 Melnick Decl. at 1 n.1 & ¶ 11 (docket no. 125-4) and Settlement Agreement at 40 (docket 22 no. 125-2 at 42)). By Order entered February 15, 2024, the Court treated the renewed 1 motion for preliminary approval of a class settlement as seeking leave to amend to add 2 Gao as a named plaintiff, granted the request, and appointed Gao, along with Nacif and

3 Rafi, as Class Representatives for the following certified class and subclasses: 4 • a class of all persons and entities who or which purchased or otherwise acquired Athira Pharma, Inc.

Free access — add to your briefcase to read the full text and ask questions with AI

Nacif v. Athira Pharma Inc, (W.D. Wash. 2024).

Nacif v. Athira Pharma Inc (Nacif v. Athira Pharma Inc) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Kunckle v. Wynick
1 U.S. 305 (Supreme Court, 1788)